Previous close | 5.95 |
Open | 6.04 |
Bid | 5.85 |
Ask | 6.15 |
Strike | 49.00 |
Expiry date | 2024-12-20 |
Day's range | 5.99 - 6.09 |
Contract range | N/A |
Volume | |
Open interest | 1.78k |
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.